GlassScriptPhysician profile
Alan Lockwood
NPI 1639702061
$1,493.76
in general payments reported to CMS, 2019-2025
20 companies · $763 in 2025
The $763 reported for 2025 was more than what 84% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
See the full distribution for Acute Care (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $37.15 · 2022: $194 · 2023: $93.33 · 2024: $406 · 2025: $763.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,262.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,262.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $491.51 | 2024-2025 | |
| Jazz Pharmaceuticals INC. | $315.32 | 2021-2025 | |
| Seagen INC. | $99.99 | 2022 | |
| Novartis Pharmaceuticals Corporation | $79.31 | 2025 | |
| Janssen Biotech, INC. | $75.87 | 2025 | Tecvayli, Carvykti, Talvey |
| Genmab U.S., INC. | $59.98 | 2025 | Tivdak, Epkinly |
| Emd Serono, INC. | $42.03 | 2025 | |
| Btg International INC. | $37.89 | 2024 | |
| Adaptive Biotechnologies Corporation | $35.80 | 2025 | Clonoseq |
| Pharmaessentia USA Corporation | $33.85 | 2024 | Besremi |
| Alexion Pharmaceuticals, INC. | $30.45 | 2025 | Ultomiris |
| Caris Mpi, INC. | $26.03 | 2025 | Mi Cancer Seek |
| Incyte Corporation | $25.34 | 2024 | Pemazyre, Monjuvi |
| Pharmacyclics LLC, An Abbvie Company | $24.58 | 2023 | Imbruvica, Epkinly |
| Immunogen, INC. | $24.36 | 2024 | Elahere |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $22.52 | 2025 | |
| Springworks Therapeutics, INC. | $20.25 | 2024 | Ogsiveo |
| Merck Sharp & Dohme LLC | $17.64 | 2025 | Keytruda, Lynparza |
| Astrazeneca Pharmaceuticals LP | $16.08 | 2025 | |
| Secura Bio, INC. | $14.96 | 2025 | Copiktra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alan Lockwood listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.